Solium Capital pullback is a buying opportunity, says Pardeep Sangha

PI analyst Pardeep Sangha says Solium Capital CEO Mike Broadfoot’s plan to sell up to 2.1-million shares is partly to blame for the stock’s recent pullback.
The pullback in price of Solium Capital (TSX:SUM) is a buying opportunity, says PI analyst Pardeep Sangha.

Noting that Solium has declined by 15% since his last published research on March 20th, Sangha today upgraded his rating on the stock from “Neutral” to “Buy”, while maintaining his $8.25 one-year target.

Sangha says recent general weakness in the tech sector and the March 21st announcement regarding Solium CEO Mike Broadfoot’s automatic securities disposition plan (ASDP) are likely the culprit for the stock’s weakness. Under the plan, Broadfoot will sell up to 2.1-million shares over the next two years.

But the PI analyst says the fundamentals on Solium remain solid, noting that the company’s recent Q4 results revealed that revenue had increased 30% year over year. Sangha says he is expecting record results for Q1, 2014 and a full fiscal year that will top 2013’s topline by 16% to reach $79-million, with EBITDA of $20-million. The following year, he expects Solium will earn $23-million on revenue of $89.5-million.

Sangha says that after trading at a premium to its peer group, Solium is now valued at 3.3x EV/Sales and 13.2x EV/EBITDA, well below its peers valuation of 4.0x EV/Sales and 14.7x EV/EBITDA.

Tagged with: sum
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Universal Display Corp a buy right now?

In an April 1 report, Roth Capital Markets analyst Scott Searle maintained his “Buy” rating and $180.00 target on Universal… [Read More]

4 days ago

This analyst loves NervGen Pharma

In a March 31 report, Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$5.50 target on NervGen… [Read More]

4 days ago

NTG Clarity Networks is a buy, this analyst says

In a March 31 initiation, Ventum Capital Markets analyst Amr Ezzat launched coverage of NTG Clarity Networks (NTG Clarity Networks… [Read More]

4 days ago

Uber is much more than you think, this investor says

In an appearance on BNN Bloomberg Market Call on March 31, Propellus Wealth Partners portfolio manager and senior wealth advisor… [Read More]

5 days ago

Canadian economy is on firmer footing than expected: RBC

In a March 31 report, RBC economist Abbey Xu said the Canadian economy started 2026 on firmer footing than expected,… [Read More]

5 days ago

Should you sell your zSpace stock?

In a March 31 report, Roth Capital Markets analyst Rohit Kulkarni maintained his “Buy” rating on zSpace (zSpace Stock Quote,… [Read More]

5 days ago